Pomerantz Law Firm Announces Class Action Lawsuit Against Zenas BioPharma: Key Details for Investors
Attention Investors: Class Action Against Zenas BioPharma
On April 28, 2025, the Pomerantz Law Firm disclosed the initiation of a class action lawsuit targeting Zenas BioPharma, Inc. (NYSE: ZBIO). The firm aims to assist investors who have suffered losses relating to their investments in Zenas. For affected investors, this is an opportunity to hold the company accountable for alleged securities fraud and other questionable business practices.
Background of the Case
Zenas BioPharma, founded in the biotechnology sector, went public on September 13, 2024, during its initial public offering (IPO). The company issued approximately 13.235 million shares at an initial price of $17.00 per share. However, issues emerged soon after. In a quarterly report dated November 12, 2024, Zenas communicated that it could only sustain its operations for
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.